If not administered properly, health experts say medications like Ozempic, Mounjaro, and Wegovy can cause gastrointestinal ...

(HealthDay News) — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

Weight-inclusive health care is the provision of equitable care without perpetuating weight stigma among patients of all body ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

We recently compiled a list of the 14 Best Large Cap Dividend Growth Stocks To Buy Now. In this article, we are going to take ...

It’s obvious these drugs are trimming waistlines across the nation; what may be less obvious is that they might also reshape ...

If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS ...

On Wednesday, state house lawmakers were considering House Bill 1451, which was seeking to require Medicaid to provide ...

Ozempic may help reduce alcohol cravings, according to a new study. But you shouldn't use them to help curb drinking habits ...